Subglottic stenosis (obstructing scar in the larynx and trachea) occurs in patients
spontaneously (idiopathic), with autoimmune disease, and after long-term breathing tube
placement and can result in communication disability and high mortality rates due to the
obstructed airway. The proposed Adjuvant EveRolimus Outcomes (AERO) trial is proof-of-concept
study using the immunosuppressant drug, everolimus, to reduce the number of surgeries for
patients with idiopathic Subglottic Stenosis (iSGS). Success with the AERO trial will allow
for everolimus to be used in subsequent larger trials of participants with laryngotracheal
stenosis and could lead to everolimus being the first FDA approved medical treatment for
iSGS.